Phase I/II randomized trial of LBH589 (Panobinostat) at two dose levels combined with bicalutamide (Casodex®) in men with castration-resistant prostate cancer
To find out how effective the study drug LBH589 (Panobinostat) and bicalutamide are against prostate cancer, based on time to prostate-specific antigen (PSA) progression, and/or progression by imaging (CT scan, bone scan) and, to find out the side effects of LBH589.
- Subjects must have prostate cancer which has not responded to initial hormone treatment and is progressing by PSA or scans.
- Subjects medical history will be reviewed in detail for study eligibility.
18 - 100
Healthy Volunteers Needed
Duration of Participation
Clinical Trials Information Line: Phone 503-494-1080 or email@example.com
New York University School of Medicine